OncoMatch/Clinical Trials/NCT07238712
Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor
Is NCT07238712 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Ruxolitinib and Abatacept (Orencia) for acute myeloid leukemia (aml).
Treatment: Ruxolitinib · Abatacept (Orencia) — Optimization of bendamustine-containg graft-versus-host disease (GVHD) prophylaxis to reduce the incidence of secondary haemophagocytic lymphohistiocytosis and GVHD
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndrome
Biomarker criteria
Required: TP53 mutation
Prior therapy
Must have received: allogeneic stem cell transplant — second or subsequent allogeneic HCT after relapse of a myeloid malignancy
Second or subsequent allogeneic HCT after relapse of a myeloid malignancy
Must have received: induction therapy — AML with >5% of clonal blasts in bone marrow despite adequate previous induction therapy
Acute myeloid leukemia: >5% of clonal blasts in bone marrow despite adequate previous induction therapy or allogeneic stem cell transplantation
Must have received: — MDS with >5% of blasts despite previous therapy
Myelodysplastic Syndrome: >5% of blasts despite previous therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify